GOP Lawmakers Challenge Treasury on 280E Tax Relief After Rescheduling

Letter Targets Tax Implications of DEA Rescheduling Rule

The June 4 letter from GOP lawmakers challenges the Treasury Department's position on how rescheduling affects Section 280E enforcement. Representatives sent the correspondence one day after the Drug Enforcement Administration published its final rule moving cannabis to Schedule III. The regulatory change took effect immediately upon Federal Register publication on June 3, 2026.

The lawmakers described themselves as "concerned" and "troubled" that state-licensed marijuana operators would gain access to standard business expense deductions currently prohibited under 26 U.S.C. § 280E. That statute bars any taxpayer trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses—a restriction that's cost the cannabis industry an estimated $1.8 billion annually in excess federal tax liability.

Schedule III substances remain federally controlled but fall outside 280E's scope. The rescheduling rule doesn't legalize marijuana for recreational purposes or remove it from the Controlled Substances Act entirely, but the schedule change alone triggers the tax code shift.

280E Has Imposed Effective Tax Rates Above 70 Percent on Cannabis Operators

Section 280E has forced state-legal cannabis businesses to pay federal income tax on gross receipts rather than net income since the statute's enactment in 1982. Industry operators have reported effective tax rates between 40 percent and 75 percent because they can't deduct rent, payroll, utilities, or marketing expenses. Only cost of goods sold can be subtracted from revenue—direct cultivation and manufacturing costs.

The tax burden created by 280E has been the single largest federal impediment to cannabis business viability, larger than banking access restrictions or state licensing costs combined.

The Congressional Research Service estimated in a 2024 report that eliminating 280E would reduce federal tax collections by approximately $5 billion over ten years, assuming current industry revenue levels. The actual figure will depend on how many state-licensed operators file amended returns and how aggressively the Internal Revenue Service audits retroactive deduction claims.

For full background on this story, see the CannIntel topic hub on DEA rescheduling.

Treasury Has Not Issued Formal Guidance on Post-Rescheduling Tax Treatment

The Internal Revenue Service has not published a revenue ruling, notice, or other formal guidance clarifying whether 280E relief applies immediately or requires additional regulatory steps. Tax practitioners have advised clients that the statute's plain language ties the prohibition to Schedule I and Schedule II substances only. Relief is automatic once the DEA rule takes effect.

Some operators have already filed amended returns for tax year 2025, claiming deductions for expenses previously disallowed under 280E. The IRS hasn't publicly stated whether it will process those claims, place them in suspense pending guidance, or initiate audits. Treasury's silence has created uncertainty for an industry that operates on thin margins even without the 280E penalty.

The GOP letter appears designed to pressure Treasury into either delaying relief or issuing restrictive guidance that narrows the scope of allowable deductions. Neither lawmaker chairs a committee with direct jurisdiction over tax policy, but both sit on subcommittees that oversee IRS appropriations.

Rescheduling Does Not Resolve State-Federal Conflicts on Legality

Moving marijuana to Schedule III leaves the substance federally controlled and doesn't grant states authority to license recreational sales. The Controlled Substances Act at 21 U.S.C. § 903 preserves state authority to impose stricter controls but doesn't permit states to authorize conduct the CSA prohibits. Schedule III drugs require a prescription under federal law. No physician can lawfully prescribe marijuana for recreational use.

The DEA's final rule applies only to medical cannabis uses recognized by the Food and Drug Administration in its scheduling recommendation. Epidiolex, a CBD-derived epilepsy treatment, remains the only FDA-approved marijuana-derived pharmaceutical. State adult-use programs operate in a legal gray zone where federal enforcement has been deprioritized but not eliminated.

Tax relief under 280E doesn't depend on whether a business's activities are federally lawful. The statute bars deductions for trafficking in Schedule I or II substances; it doesn't require legality. A Schedule III cannabis operator remains in violation of the CSA if operating without DEA registration, but that violation no longer triggers 280E.